Axol Biosciences offers new screening assay for hiPSC-derived cells

By The Science Advisory Board staff writers

October 13, 2020 -- Axol Biosciences has added multielectrode array (MEA) screening services for human-induced pluripotent stem cell (hiPSC)-derived cells to its service offering for preclinical drug discovery.

The company said that its new MEA screening services optimize hiPSC-derived cell culture, while also providing electrophysiology acquisition and analysis from physiologically relevant human cell models.

The expansion combines Axol's hiPSC-derived human cells and electrophysiological experience with Axion Biosystems' Maestro Pro MEA platform, according to the firm. The Maestro Pro supports continuous label-free and real-time data acquisition and analysis from 768 electrodes in up to a 96 wp format, Axol said.

Curi Bio launches ComboMat to aid preclinical drug development
Curi Bio released its new proprietary ComboMat platform, a human induced pluripotent stem cell cardiomyocyte maturation technology with applications in...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter